Suppr超能文献

不同剂量的SP 54对血栓性疾病患者纤溶活性的影响。

Effects of various doses of SP 54 on fibrinolytic activity in patients with thrombotic diseases.

作者信息

Losonczy H, Nagy I, Dávid M

机构信息

First Department of Internal Medicine, Medical School Pécs, Hungary.

出版信息

Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(3):388-93.

PMID:2465236
Abstract

SP 54 was synthetized more than 30 years ago, but the proper oral dosage has not been established yet. Therefore we gave two doses. 150 and 500 mg to patients suffering from various arterial and venous thrombotic diseases, for investigating the dose-response effect. 16 patients received 150 mg, 14 patients 500 mg and 10 in each group both doses. We could observe significant changes in ELT, WBL and plasminogen level, but the increase of fibrinolytic activity was not dose-dependent in most cases. It indicates that an individual dosage is needed. Therefore we suggest an "SP 54 loading test" before prescribing the drug.

摘要

SP 54于30多年前合成,但尚未确定合适的口服剂量。因此,我们给患有各种动静脉血栓性疾病的患者服用了两个剂量,即150毫克和500毫克,以研究剂量反应效应。16名患者接受了150毫克剂量,14名患者接受了500毫克剂量,每组各有10名患者接受了两种剂量。我们可以观察到优球蛋白溶解时间、白细胞计数和纤溶酶原水平有显著变化,但在大多数情况下,纤溶活性的增加并不依赖于剂量。这表明需要个体化给药。因此,我们建议在开药前进行“SP 54负荷试验”。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验